Pfizer to buy Metsera for $47.50 a share, with up to $22.50 more tied to milestones

Pfizer has agreed to pay $47.50 in cash for each share of Metsera, a clinical-stage developer of obesity and cardiometabolic medicines, the two companies said on September 22, 2025 ^[1]. Shareholders would also receive a contingent value right that can pay up to $22.50 more per share if three specific goals are reached ^[1]. Pfizer put the up-front value of the deal at approximately $4.9 billion ^[1].

Metsera was founded in 2022 and is based in New York City ^[1]. Its drug candidates are in Phase 1 and Phase 2 testing, and none is approved for sale ^[1].

How the extra payments work

The contingent value right is divided into three parts, each tied to a separate event ^[1]:

• $5 per share if Metsera starts a Phase 3 trial of its MET-097i plus MET-233i combination.
• $7 per share if the FDA approves monthly MET-097i used alone.
• $10.50 per share if the FDA approves the monthly MET-097i plus MET-233i combination.

Metsera shareholders would have to wait for those events, and there is no guarantee any of them occurs.

What Pfizer is buying

MET-097i is an injectable GLP-1 receptor agonist in Phase 2 development, tested as both a weekly and a monthly dose ^[1]. MET-233i is a monthly amylin analog in Phase 1, studied on its own and together with MET-097i ^[1]. Two oral GLP-1 receptor agonist candidates are expected to begin clinical trials soon, and Metsera has additional preclinical nutrient-stimulated hormone programs ^[1].

Pfizer said initial Phase 1 results for MET-233i were presented September 17, 2025 as a late-breaker at the 61st Annual Meeting of the European Association for the Study of Diabetes, and described the data as showing a potential best-in-class profile ^[1]. That is Pfizer's characterization of the results. Findings from larger trials have not been reported.

"Obesity is a large and growing space with over 200 health conditions associated with it," Pfizer chief executive Albert Bourla said in the announcement. "The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area" ^[1].

Metsera co-founder and chief executive Whit Bernard said the company has "invented and developed multiple injectable and oral candidate medicines and a category-leading peptide engineering platform," adding that the deal "sets a path for our portfolio to potentially transform the lives of hundreds of millions of people" ^[1].

Why it matters for patients

People now taking approved GLP-1 medicines will not see any change from this announcement. Ozempic, Wegovy and Rybelsus are all semaglutide, and Mounjaro and Zepbound are tirzepatide. None of those products is part of the transaction ^[1].

The part that could eventually matter is how often a shot is needed. Metsera is testing a monthly version of its lead injectable rather than only a weekly one, and Pfizer's announcement treats monthly dosing as a selling point, describing candidates aimed at "fewer injections" ^[1]. A shot once a month instead of once a week would mean fewer needles a year for people who dislike injections or travel often.

Whether the monthly versions control weight, appetite and blood sugar as well as existing weekly drugs is not established. No head-to-head studies against approved medicines have been reported, and neither candidate has completed the large trials needed for FDA review.

Pricing, insurance coverage and a possible launch date for any of these candidates have not been disclosed ^[1].

What happens next

Pfizer expects the acquisition to close in the fourth quarter of 2025, subject to regulatory approvals and a vote by Metsera shareholders ^[1]. Pfizer said it will provide any updates to its financial outlook along with its upcoming quarterly earnings ^[1].

The milestone payments depend on events that have no announced dates, including the Phase 3 trial start and the two FDA approvals ^[1].